Ranibizumab  (Synonyms: 雷珠单抗; RG-6321)

Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)^[1]. Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research^[1].

Ranibizumab (RG-6321) 是一种人源化抗 VEGF 单克隆抗体片段 (IgG 抗原结合片段 (Fab-Y0317)^[2]。Ranibizumab (0.0625-0.25 mg/mL；72 小时) 导致大鼠视网膜细胞培养物中坏死和细胞凋亡增加^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

对猴子的研究表明，在单次玻璃体内给药后，Ranibizumab 可以迅速分布到视网膜 (6-24 小时)。在家兔玻璃体内注射 Ranibizumab 仅需 1 小时后，Ranibizumab 可快速穿透视网膜到达脉络膜^[1]。
在一项比较 0.5 mg Ranibizumab 与 1.25 mg Ranibizumab 玻璃体内注射的药代动力学的研究中，在兔玻璃体腔注射 Bevacizumab (HY-P9906) 时，Ranibizumab 的玻璃体半衰期为 2.88 天，比 Bevacizumab 的 4.32 天半衰期短。Bevacizumab 和 Ranibizumab 处理 3 天后，眼房水中的峰值浓度分别为 37.7 μg/mL 和 17.9 μg/mL^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

347396-82-1

液体

Colorless to light yellow

雷珠单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mustafa Şahiner, et al. The Effects of Anti-Vascular Endothelial Growth Factor Drugs on Retinal Pigment Epithelial Cell Culture. Turk J Ophthalmol. 2018 Aug;48(4):190-195.  [Content Brief]

  [2]. K J Kim, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7(1):53-64.  [Content Brief]

  [3]. Richard Filek, et al. Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. Clin Ophthalmol. 2019 Jul 1;13:1097-1114.  [Content Brief]